Investment Thesis
Constellation Pharmaceuticals share price performance since IPO. Source: TradingView.
Since launching a scaled-down IPO in July 2019 at $15 per share that raised ~$60m - as opposed to the $80m it had originally sought - Constellation Pharmaceuticals (CNST) has delivered outstanding results for its shareholders.
The epigenetics specialist has put together a small but promising pipeline of small molecule inhibitors targeting a rare form of blood cancer, Myelofibrosis, as well as solid tumor treatments.
The major catalyst for Constellation's share price growth from a low of $6 to a mid-May